May 2024
No | Study Name/Phase | Type | Sponsor | Population (Gender/Age) | Enrolled / (Target if still enrolling) | Period |
Setshaba Research Centre: Site Initiated Research | ||||||
1 |
Vaccine Hesitancy |
Behavioural | SRC | ♂/♀≥18 | n/a | 2022 |
2 | HVTN 702/705 Mapping click to read more | Behavioural | SRC | ♂/♀18-35 yrs | n/a | 2020-2021 |
Other Projects | ||||||
3 | R01 AI147681 KHARITUWE TB MIGRATION STUDY | TB Tracing | John Hopkins University | ♂/♀ 0-99 yrs | target 7200 | 2020 – 2025 |
4 | HVTN RAMP | Behavioural | HVTN | MSM &Transgender ♂ ≥18;
Transgender ♀ ≥18 |
200 | May 2021 – May 2022 |
5 |
GS-US-412-5624 (PURPOSE 1) |
HIV PrEP study | Gilead | Cisgender ♀ 16 – 35 |
200 | Nov/2021 – Jun/2026 |
6 | HVTN 139 Phase 1 | HIV Vaccine Study | HVTN | ♂+♀18 through to 50 years | 6 | Nov/2021 – Dec/2023 |
7 | Pfizer RSV Phase 3 | RSV Vaccine | Pfizer | ♂+♀ ≥ 60 |
100 | Nov/2021 – Dec/2022 |
8 | Gates MRI TBV02-EO1 | Epidemiology | Bill and Melinda Gates | ♂+♀15 – 34 | 160 | Jan 2022 – Jun 2025 |
9 | GO-012 | Covid Vaccine | Gritstone Bio | ♂+♀18 – 64 | 94 | Mar 2022 – Mar 2023 |
10 | 323-201-00006_Otsuka Trial – 2b/c | TB Oral treatment Study | Clindev | ♂+♀ 18-65 | 15 | APR/2022-APR/2024 |
11 | GS-US-528-9023_(Purpose 2) | HIV PrEP study | Gilead | Cisgender ♀
16 – 35 |
75 | Jul 2022 – 2026 |
12 | VAC31518COV3006_Horizon 2 | Covid Vaccine | Janssen | <12 years
≥18 |
19 | Jun 2022 – Jun 2024 |
13 | GBS_MVX0004 | Group B Streptococcus | MinerVax/OnQ | ♀
18 years and older |
50 | Aug 2022-Aug 2023 |
14 | RSV-MAT 015 | Observational study | GSK | ♀
18 – 49 |
150 | Mar 2023 – 2024 |
15 | Pfizer Flu (C4781004) | Flu vaccine study | Pfizer | ♂+♀ 65 years and above | Target 200
Enrolled 208 |
Jun 2023-2024 |
16 | NC009 | TB Study | TB Alliance | ♂+♀ 18 – 65 years | Target 15
Enrolled 3 |
Oct 2023 –Nov 2024 |
17 | HVTN 605 | TB Vaccine | DAIDS | ♂+♀ 12 – 55 years | Target 60
Enrolled 30 |
Feb 2024 – 2025 |
18 | TB Gates MRI TBV02-301 | TB Vaccine | Bill & Mellinda Gates Fondation | ♂+♀ 15 – 44 years | Target 1155
Enrolled 86 |
Mar 2024- 2028 |
19 | C3671032 Pfizer RSV | RSV Vaccine | Pfizer | ♀ Pregnant (24 weeks) | Target
Enrolled |
Mar 2024 – Jan 2026 |
OUR EXPERIENCE
COVID-19
Areas of Expertise
Completed Projects
Current Projects